3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow Hemosiderosis: new trials by email Literature Review of Hemosiderosis trials Research Report on Hemosiderosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Efficacy of Deferasirox in MDS Deferasirox - Myelodysplastic Syndromes, Hemosiderosis | Phase 3 | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 158 | 2007-06-01 | 2016-11-22 |
| A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis deferasirox - Beta-Thalassemia, Hemosiderosis | Phase 3 | Completed | Novartis | 252 | 2004-05-01 | 2017-03-01 |
| Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions ICL670, deferoxamine - Beta-Thalassemia | Phase 3 | Completed | Novartis Pharmaceuticals | 595 | 2003-05-01 | 2012-04-19 |
Thalassemia (2) · beta-Thalassemia (2) · Iron Overload (1) · Myelodysplastic Syndromes (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Iron Metabolism Disorders (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Anemia (2) · Anemia, Hemolytic (2) · Anemia, Hemolytic, Congenital (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Hemoglobinopathies (2) · Iron Overload (2) · Bone Marrow Diseases (1)
Deferasirox (3) · Deferoxamine (1)
Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Novartis (1) · Novartis Pharmaceuticals (1)
Egypt (1) · Italy (1) · Lebanon (1) · Oman (1) · Saudi Arabia (1) · Syria (1) · United States (1)